Background and Objectives: The aim of the study is to evaluate the
therapeutic efficacy and safety of Yttrium- 90 radiolabelled chimeric anti CD20
antibody-Rituximab in the treatment of patients with relapsed/ refractory B cell
Non-Hodgkins Lymphoma (NHL).
Methods: Twenty patients with relapsed/refractory CD20+ NHL in progressive
state were included in the study. These patients had undergone a median of 2
(range 2-5) prior standard chemotherapy ± immunotherapy regimens. All the patients
received rituximab 250 mg/m2 on days 1 and 8, and either 14 MBq/kg (0.4
mCi/kg) or 11 MBq/kg (0.3 mCi/kg) of Y-90 Rituximab on day 8 (maximum dose,
32 mCi) depending upon their platelet count. The patients were observed for systemic
toxicity and response for at least 12 weeks after therapy.
Results: No acute adverse effects were observed after the administration of 90Y-Rituximab. Overall
response rate (ORR) was 45% of which complete response (CR) was observed in 2 patients, stable
disease in 1 patient and partial response in 6 patients. The therapy was well tolerated with grade IV
thrombocytopenia, neutropenia and anemia observed in 3, 4 and 2 patients respectively.
Conclusion: 90Y-Rituximab therapy is safe and well tolerated in high risk extensively pretreated
NHL patients. Toxicity is primarily hematologic, transient and reversible.